Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis (Taba-Muco)

University Hospital, Strasbourg, France

Status: Enrolling

Conditions: Cystic Fibrosis

Study type: Observational

Funder types: Other

Identifiers

NCT07342920

9813

Details and patient eligibility

About

In the collective unconscious, a patient with cystic fibrosis does not smoke. This belief is so deeply rooted that there is virtually no French data on the prevalence of smoking among this vulnerable population.

Faced with a cohort of patients undergoing a complete transformation (improved quality of life and life expectancy, fewer hospitalizations, reduced respiratory symptoms, better social integration), it is becoming urgent to assess the current situation in order to optimize tobacco prevention.

This is all the more important given the emergence of international studies objectively examining the interactions between smoking, vaping, and the efficacy of Kaftrio.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patient (≥ 18 years old)
• With confirmed cystic fibrosis
• Regular follow-up at the Strasbourg Adult Cystic Fibrosis Center

Exclusion criteria

• Patients who have undergone a double lung transplant for cystic fibrosis.